Inside the research
Edwards Lifesciences Corporation
EW Research profile · latest available data
Price overview
$86.29
▲ +0.56 (+0.7%)
| 52w hi | $95.18 |
|---|---|
| 52w lo | $72.65 |
| Vol | 3.60M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.06
| Short | +0.13 |
|---|---|
| Medium | +0.11 |
| Long | -0.16 |
computed 2026-09-27
Key fundamentals
Edwards Lifesciences Corporation
Healthcare · Medical Devices
| Market cap | $49.74B |
|---|---|
| Enterprise value | $46.30B |
| Trailing P/E | 51.36x |
| Forward P/E | 25.55x |
| EV / EBITDA | 23.18x |
| P / S (ttm) | 7.63x |
| Profit margin | 15.4% |
| Return on equity | 9.2% |
| Revenue growth | +13.6% |
| Earnings growth | -25.4% |
| Debt / equity | 6.57 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.07 | |
| Sector | +0.08 | |
| Technical | -0.03 | |
| Earnings | +0.00 | |
| Sentiment | +0.18 |
macro × 1.00 · 2026-09-27
Business overview
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Risk Metrics
| Beta vs SPX | 0.55 |
|---|---|
| Corr SPX | 0.36 |
| Annual vol | 24.9% |
| Annual ret | +15.9% |
| Sharpe | 0.64 |
| Max DD | -13.2% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $97.15 |
|---|---|
| High / Low | $110.00 / $84.00 |
| Median | $100.00 |
| Analysts | 27 |
| Strong Buy | 5 | |
|---|---|---|
| Buy | 17 | |
| Hold | 8 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-27 | Barclays | → Overweight |
| 2026-04-24 | Truist Securities | → Hold |
| 2026-04-24 | Evercore ISI Group | → Outperform |
| 2026-04-24 | Canaccord Genuity | → Hold |
| 2026-04-24 | BTIG | → Buy |
| 2026-04-24 | Baird | → Neutral |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-23 | Earnings Release, Exhibits | read |
| 2026-05-08 | Officer / Director Change, Shareholder Vote… | read |
| 2026-05-04 | Officer / Director Change, Reg FD Disclosure | read |
| 2026-04-23 | Earnings Release, Exhibits | read |
| 2026-02-10 | Earnings Release, Exhibits | read |
| 2026-01-12 | Reg FD Disclosure, Exhibits | read |
| 2025-10-30 | Earnings Release, Exhibits | read |
| 2025-10-30 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-08-19 | Other Material Event, Exhibits | read |
| 2025-08-06 | Reg FD Disclosure, Exhibits | read |
| 2025-07-25 | Officer / Director Change | read |
| 2025-07-24 | Earnings Release, Exhibits | read |
SEC Filings
The Long Run
FY 2010–2025 · 16 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $5.44B | +20.4% | |
| Gross profit | $4.32B | +10.0% | |
| Operating income | $1.26B | +2.1% | |
| Net income | $1.07B | -12.5% | |
| Cash from ops | $895.80M | +15.2% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $86.66 | $87.11 | $84.93 | $86.29 | 3.60M |
| Sep 24 | $86.54 | $87.12 | $85.63 | $85.73 | 3.87M |
| Sep 23 | $88.70 | $88.79 | $86.06 | $86.82 | 3.62M |
| Sep 22 | $89.00 | $89.66 | $88.50 | $88.78 | 3.53M |
| Sep 21 | $88.34 | $88.59 | $87.77 | $88.34 | 3.35M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →